Stephen Martin, after leaving Applied Biosystems (see PM 6-4-04), has resurfaced at Beyond Genomics, where he has become senior vice president and chief technical officer. Prior to joining Beyond Genomics, he was the senior director of the Discovery Proteomics and Small Molecule Research Center at ABI. Martin holds a PhD in analytical chemistry from MIT and a BA in chemistry from Boston University.
Craig Mello has become a scientific advisor for Invitrogen in the area of RNAi research. He is a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor’s degree in biochemistry from Brown University.
William Castell has become vice chairman of the board of directors of General Electric. Castell will remain in Chalfont St. Giles, UK. He became president and CEO of GE Healthcare in April, following GE’s acquisition of Amersham, the company he joined as CEO in 1989. Castell is also an executive officer and a member of the corporate executive office of GE. He holds a BA in business studies from the City of London College.
Melvin Booth has joined the board of directors of Billerica, Mass.-based Millipore. Until his retirement in January, he was president and chief operating officer of MedImmune. Prior to that, he was president and COO of Human Genome Sciences. Booth holds a doctor of science degree from Northwest Missouri State University.
Stanley Appel has become chairman of the scientific advisory board of The Woodlands, Texas-based Power3 Medical Products. He is currently also chairman of the department of neurology at Baylor College of Medicine.